Skip to main content

Day: August 13, 2021

ProPhase Labs Announces Financial Results for the Quarter Ended June 30, 2021

Company Provides Update on Significant Resurgence in Covid testing and Additional Insights into Previously Announced Nebula Genomics Acquisition Company to hold a conference call today at 11:00AM ET Garden City, NY, Aug. 13, 2021 (GLOBE NEWSWIRE) — ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified biotech and genomics company, today reported its financial and operational results for the quarter ended June 30, 2021. Financial highlights for the quarter ended June 30, 2021 include the following:Total revenue of $9.1 million for the quarter ended June 30, 2021, as compared to $3.6 million for the quarter ended June 30, 2020, an increase of approximately 153%. Net loss for the quarter ended June 30, 2021 of $1.4 million, or $(0.09) per share, as compared to net income of $70,000, or $0.01 per share, for the quarter ended June 30,...

Continue reading

Outlook Therapeutics Reports Financial Results for Third Quarter of Fiscal Year 2021 and Provides Corporate Update

Reported positive, statistically significant top-line efficacy and safety data from pivotal Phase 3 NORSE TWO trial of ONS-5010 / LYTENAVA™ (bevacizumab-vikg) for the treatment of wet age-related macular degeneration (wet AMD)On track to submit new U.S. BLA for ONS-5010 in the first quarter of calendar 2022 and pre-commercial launch planning underwayISELIN, N.J., Aug. 13, 2021 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced recent corporate highlights and financial results for its fiscal third quarter ended June 30, 2021. Outlook Therapeutics also provided a clinical development and pre-commercialization update on ONS-5010 / LYTENAVA™ (bevacizumab-vikg),...

Continue reading

Middlefield Banc Corp. Increases Share Repurchase Program

MIDDLEFIELD, Ohio, Aug. 13, 2021 (GLOBE NEWSWIRE) — Middlefield Banc Corp. (NASDAQ: MBCN) today announced its Board of Directors approved additional share repurchase capacity for the Company’s repurchase program (the “Program”). “With strong capital levels, and excess liquidity, we believe investing in our common stock at compelling valuations is a good return for our shareholders. In addition, the expanded repurchase program demonstrates our confidence in the strength of our business and our continued commitment to delivering value to our shareholders. Since April 2019, we have repurchased 527,143 shares of our common stock at an average price of $18.52 per share,” said Thomas G. Caldwell, Middlefield’s President and Chief Executive Officer. On August 9, 2021, Middlefield’s Board of Directors authorized the Company to repurchase...

Continue reading

Ollie’s Bargain Outlet Holdings, Inc. Announces Second Quarter Fiscal 2021 Release Date and Conference Call Information

HARRISBURG, Pa., Aug. 13, 2021 (GLOBE NEWSWIRE) — Ollie’s Bargain Outlet Holdings, Inc. (NASDAQ: OLLI) (the “Company”) announced today that it will release its financial results for the second quarter of fiscal 2021 on Thursday, August 26, 2021 after the market closes.   Following the release, at 4:30 p.m. Eastern Time the Company’s management team will host a conference call to discuss its results. Investors and analysts can participate on the conference call by dialing (800) 219-7052 or (574) 990-1029 and using conference ID #7495397. Interested parties can also listen to a live webcast or replay of the conference call by logging on to the Investor Relations section on the Company’s website at http://investors.ollies.us/. About Ollie’sWe are a highly differentiated and fast growing, extreme value retailer of brand name merchandise...

Continue reading

MedX Holdings Inc. Acquires Dazed Inc., to Expand into Cannabis Retail and Public Consumption

CHEYENNE, Wyo., Aug. 13, 2021 (GLOBE NEWSWIRE) — MedX Holdings Inc. (OTC: MEDH) (“MEDH” or the “Company”), a brands management and acquisition company, today announces it is acquiring Dazed Inc., as a wholly owned subsidiary. Dazed Inc, a Texas company, established in 2007 has an operating history of over 15 years in the cannabis space which includes related products and services. Dazed Inc. is ever-expanding, even Rolling Stone gave the brand a shout-out in the popular Willie Nelson issue. The brick and mortar concept, The Lazydaze brand was established in 2004, and is perfectly positioned for the inevitable legalization of cannabis. “With federal legalization on the horizon, we are confident that offering the two most consumed commodities in the world, coffee and cannabis, under one roof is a homerun. There is an obvious need...

Continue reading

Ayala Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update

– Enrolled the First Patient in the Phase 2/3 Pivotal Trial of AL102 for the Treatment of Desmoid Tumors – Multiple Near-Term Milestones Across Clinical-Stage Pipeline – Updated ACCURACY Trial Data to Be Presented at ESMO 2021- REHOVOT, Israel and WILMINGTON, Del., Aug. 13, 2021 (GLOBE NEWSWIRE) —  Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, today reported financial results for the period ended June 30, 2021 and highlighted recent progress and upcoming milestones for its pipeline programs. “Ayala is well positioned for strong clinical progress throughout the remainder of this year. In the second quarter,...

Continue reading

Marathon Digital Holdings Reports Second Quarter 2021 Results

Revenues Increase 220% Q2 over Q1 2021 and 10,147% Year-over-Year to $29.3 Million with Non-GAAP Income from Operations of $20.1 Million LAS VEGAS, Aug. 13, 2021 (GLOBE NEWSWIRE) —  Marathon Digital Holdings, Inc. (NASDAQ:MARA) (“Marathon” or “Company”), one of the largest enterprise Bitcoin self-mining companies in North America, reported financial results for the second quarter ended June 30, 2021. Second Quarter and Recent Financial HighlightsIncreased total revenue to $29.3 million, a 220% increase from $9.2 million in the first quarter of 2021 and a 10,147% increase year-over-year from $286,000 in the second quarter of 2020 Produced 654 newly minted bitcoins in the second quarter of 2021; as of June 30, 2021, produced 846 newly minted bitcoins in 2021 Marathon’s investment fund, which purchased 4,812.66...

Continue reading

PMV Pharmaceuticals Reports Second Quarter 2021 Financial Results and Corporate Highlights

Continued enrollment in Phase 1/2 trial of first-in-class p53 Y220C reactivator PC14586CRANBURY, N.J., Aug. 13, 2021 (GLOBE NEWSWIRE) — PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a clinical-stage oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies designed to target p53 mutants, today reported financial results for the second quarter ended June 30, 2021 and provided corporate highlights. “We are encouraged by our execution in the clinic, with steady progress in the ongoing Phase 1/2 trial of PC14586,” said David Mack, Ph.D., President and Chief Executive Officer of PMV Pharma. “We believe PC14586, our first-in-class, tumor agnostic, p53 Y220C reactivator has the potential to transform outcomes for cancer patients. Furthermore, our strong balance sheet leaves us well positioned...

Continue reading

Twin Disc, Inc. Announces Fiscal 2021 Fourth Quarter Financial Results

• Fourth quarter sales up 11.5% year-over-year • Fourth quarter gross profit percent improved 440-basis points year-over-year • Strong operating cash flow and improving profitability drives net debt to lowest level in three years • Restructuring actions in the quarter to drive approximately $2 million of annualized savings • Management optimistic recovery is underway RACINE, Wis., Aug. 13, 2021 (GLOBE NEWSWIRE) —  Twin Disc, Inc. (NASDAQ: TWIN), today reported financial results for the fiscal 2021 fourth quarter ended June 30, 2021. Sales for the fiscal 2021 fourth quarter were $66.2 million, compared to $59.4 million for the same period last year, and $57.6 million for the fiscal 2021 third quarter. The 11.5% year-over-year increase in 2021 fourth quarter sales was primarily due to improving demand within the Company’s global...

Continue reading

Alimera Sciences Announces Second Quarter 2021 Financial Results

Consolidated Net Revenue of $21.7 Million up 117% vs. Second Quarter of 2020 Consolidated Net Product Revenue of $10.7 Million up 7% vs. Second Quarter of 2020 Net Income of $7.6 Million vs. Net Loss of $2.5 Million in Second Quarter of 2020 End User Demand up 16% on a Same Country Basis vs. Second Quarter of 2020ATLANTA, Aug. 13, 2021 (GLOBE NEWSWIRE) — Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the treatment of retinal diseases, today announced financial results for the second quarter of 2021. Alimera will host a conference call today at 9:00 a.m. EDT to discuss these results. “Although the ongoing COVID-19 pandemic continues to impact the delivery of healthcare around the world and...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.